8th German Pharm-Tox Summit

Molecular prediction of clinical response to anti-PD-1/anti-PD-L1 immune checkpoint inhibitors: new perspectives for precision medicine and mass spectrometry-based investigations.

Cancer pharmacology	

Cancer pharmacology and treatment

Oral presentation

Pharmacogenomics and personalized medicine	

PANHPVAX: Study design for dose titration of two first-in-human molecules (human papillomavirus L2 antigen with cyclic di-AMP) in a single vaccine trial

Disease models, drug development

<B>Posters will be presented during the time period mentioned above. This will give all participants and the poster jury the opportunity to interact with the presenting authors. Please be available to answer questions at your poster during the poster session.  

Session 1

Poster

Immunopharmacology / inflammation / anti-infectives	

P-glycoprotein inhibition by rifabutin distinguishes it from rifampicin and partly explains the unequal drug interaction risk

Drug transport/delivery and metabolism

Drug transport, metabolism and pharmacogenomics 

Pharmacokinetics and PK/PD modelling	

Desorption/ionization mass spectrometric methods for drug quantification in biological matrices and their validation following regulatory guidance.

<B>Posters will be presented during the time period mentioned above. This will give all participants and the poster jury the opportunity to interact with the presenting authors. Please be available to answer questions at your poster during the poster session. </B>


Session 2

Voriconazole clearance can be predicted by CYP3A and CYP2C19 activity using microdosed probe drugs

Prof. Dr.

Walter E. Haefeli

Further involvements